Skip to main content
NCBI home page
Gut logoLink to Gut
. 1986 Nov;27(11):1306–1311. doi: 10.1136/gut.27.11.1306

Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy.

H Sandberg-Gertzén, G Järnerot, K Bukhave, K Lauritsen, J Rask-Madsen
PMCID: PMC1434079  PMID: 2878859

Abstract

Azodisal sodium is a highly effective means of oral delivery of 5-amino-salicylic acid to the colonic mucosa. Administration of this drug to patients intolerant of sulphasalazine, however, occasionally results in liquid stools. In preliminary experiments, which comprised 10 healthy volunteers treated with colectomy for ulcerative colitis, ileostomy fluid output increased (p less than 0.001) during oral intake of azodisal sodium (1 g/day). In a double blind, placebo controlled crossover study, comprising eight similar volunteers, ileostomy fluid output increased (p less than 0.05) in a dose related manner during intake of azodisal sodium (1 g/day vs 2 g/day) compared with placebo or sulphasalazine (2 g/day). Concentrations of prostaglandin (PG)F2 alpha in free ileal water determined by equilibrium in vivo dialysis of ileostomy contents decreased (p less than 0.05) during intake of azodisal sodium (2 g/day), whereas concentrations of PGE2 and the output of PGE2, PGF2 alpha, and 'PGE2 + PGF2 alpha' remained unchanged. Thus increased formation of PGs is apparently not the cause of increased ileostomy fluid output associated with azodisalicylate intake.

Full text

PDF
1306

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Austin C. A., Cann P. A., Jones T. H., Holdsworth C. D. Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis. Lancet. 1984 Apr 21;1(8382):917–918. doi: 10.1016/s0140-6736(84)91386-2. [DOI] [PubMed] [Google Scholar]
  2. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  3. BARON J. H., CONNELL A. M., LENNARD-JONES J. E., JONES F. A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962 May 26;1(7239):1094–1096. doi: 10.1016/s0140-6736(62)92080-9. [DOI] [PubMed] [Google Scholar]
  4. Bukhave K., Gréen K., Rask-Madsen J. Comparison of radioimmunological determinations with gas chromatography mass spectrometry dosage. A study of PGE2 and PGF2alpha in gastrointestinal fluids. Biomed Mass Spectrom. 1983 Apr;10(4):265–268. doi: 10.1002/bms.1200100406. [DOI] [PubMed] [Google Scholar]
  5. Bukhave K., Rask-Madsen J. Prostaglandin E2 in jejunal fluids and its potential diagnostic value for selecting patients with indomethacin-sensitive diarrhoea. Eur J Clin Invest. 1981 Jun;11(3):191–197. doi: 10.1111/j.1365-2362.1981.tb01840.x. [DOI] [PubMed] [Google Scholar]
  6. DICK A. P., GRAYSON M. J., CARPENTER R. G., PETRIE A. CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS. Gut. 1964 Oct;5:437–442. doi: 10.1136/gut.5.5.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Das K. M., Eastwood M. A., McManus J. P., Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973 Sep 6;289(10):491–495. doi: 10.1056/NEJM197309062891001. [DOI] [PubMed] [Google Scholar]
  8. Dissanayake A. S., Truelove S. C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut. 1973 Dec;14(12):923–926. doi: 10.1136/gut.14.12.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goldman P. Will there be a next generation of sulfasalazine? Gastroenterology. 1982 Nov;83(5):1138–1141. [PubMed] [Google Scholar]
  10. Klotz U., Maier K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 Dec 25;303(26):1499–1502. doi: 10.1056/NEJM198012253032602. [DOI] [PubMed] [Google Scholar]
  11. LENNARD-JONES J. E., LONGMORE A. J., NEWELL A. C., WILSON C. W., JONES F. A. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut. 1960 Sep;1:217–222. doi: 10.1136/gut.1.3.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lauritsen K., Hansen J., Bytzer P., Bukhave K., Rask-Madsen J. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Gut. 1984 Nov;25(11):1271–1278. doi: 10.1136/gut.25.11.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lauritsen K., Hansen J., Ryde M., Rask-Madsen J. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology. 1984 Jun;86(6):1496–1500. [PubMed] [Google Scholar]
  14. Peppercorn M. A., Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology. 1973 Feb;64(2):240–245. [PubMed] [Google Scholar]
  15. Ring F. A., Hershfield N. B., Machin G. A., Scott R. B. Sulfasalazine-induced colitis complicating idiopathic ulcerative colitis. Can Med Assoc J. 1984 Jul 1;131(1):43–45. [PMC free article] [PubMed] [Google Scholar]
  16. Ruppin H., Domschke S. Acute ulcerative colitis--a rare complication of sulfasalazine therapy. Hepatogastroenterology. 1984 Aug;31(4):192–193. [PubMed] [Google Scholar]
  17. Sandberg-Gertzén H., Järnerot G., Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology. 1986 Apr;90(4):1024–1030. doi: 10.1016/0016-5085(86)90882-6. [DOI] [PubMed] [Google Scholar]
  18. Sandberg-Gertzén H., Ryde M., Järnerot G. Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. Scand J Gastroenterol. 1983 Jan;18(1):107–111. doi: 10.3109/00365528309181568. [DOI] [PubMed] [Google Scholar]
  19. Schröder H., Campbell D. E. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539–551. doi: 10.1002/cpt1972134539. [DOI] [PubMed] [Google Scholar]
  20. Schwartz A. G., Targan S. R., Saxon A., Weinstein W. M. Sulfasalazine-induced exacerbation of ulcerative colitis. N Engl J Med. 1982 Feb 18;306(7):409–412. doi: 10.1056/NEJM198202183060708. [DOI] [PubMed] [Google Scholar]
  21. WRONG O., METCALFE-GIBSON A., MORRISON R. B., NG S. T., HOWARD A. V. IN VIVO DIALYSIS OF FAECES AS A METHOD OF STOOL ANALYSIS. I. TECHNIQUE AND RESULTS IN NORMAL SUBJECTS. Clin Sci. 1965 Apr;28:357–375. [PubMed] [Google Scholar]
  22. Werlin S. L., Grand R. J. Bloody diarrhea--a new complication of sulfasalazine. J Pediatr. 1978 Mar;92(3):450–451. doi: 10.1016/s0022-3476(78)80446-6. [DOI] [PubMed] [Google Scholar]
  23. Willoughby C. P., Aronson J. K., Agback H., Bodin N. O., Truelove S. C. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut. 1982 Dec;23(12):1081–1087. doi: 10.1136/gut.23.12.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. van Hees P. A., Bakker J. H., van Tongeren J. H. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980 Jul;21(7):632–635. doi: 10.1136/gut.21.7.632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. van Hees P. A., Tuinte J. H., van Rossum J. M., van Tongeren J. H. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut. 1979 Apr;20(4):300–304. doi: 10.1136/gut.20.4.300. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES